BioAtla (BCAB) Receivables - Other (2025 - 2026)

BioAtla (BCAB) posted quarterly Receivables - Other of $4.5 million for Q1 2026, up 45.16% quarter-over-quarter from $3.1 million in Q4 2025.

BioAtla (BCAB) Receivables - Other (2025 - 2026) Analysis & Trends

BioAtla's Receivables - Other history runs 2 years deep, the most recent figure standing at $4.5 million for Q1 2026.

In Q1 2026, Receivables - Other changed N/A year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (changed N/A YoY), while the FY2025 annual figure was $3.1 million, changed N/A from the prior year.
Receivables - Other for Q1 2026 stood at $4.5 million, up from $3.1 million in the prior quarter.
The five-year high for Receivables - Other was $4.5 million in Q1 2026, with the low at $3.1 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	140.01 Bn	132.16 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.79 Bn	78.79 Bn	3.93 Bn
3	Argenx Se	65.29 Bn	60.11 Bn	1.37 Bn
4	Moderna	60.18 Bn	55.04 Bn	52.00 Mn
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.55 Bn	28.24 Bn	992.69 Mn
7	BioNTech SE	28.45 Bn	10.06 Bn	668.28 Mn
8	Insmed	27.45 Bn	26.29 Bn	358.27 Mn
9	Royalty Pharma	27.19 Bn	26.36 Bn	-
10	BioAtla	5.39 Mn	5.39 Mn	-

Download Data